Changing the World of

Alzheimer's Disease Research

An internationally recognized expert in the mechanisms of neurodegenerative diseases, Dr. Dale Bredesen’s career has been guided by a simple idea: that Alzheimer’s as we know it is not just preventable, but reversible. Dr. Bredesen’s dedicated pursuit of the science that makes this a reality has placed him at the vanguard of neurological research and led to the discoveries that today underlie the ReCODE Protocol™.

Dr. Bredesen earned his M.D. from Duke University Medical Center and served as Chief Resident in Neurology at the University of California, San Francisco (UCSF), before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA, and the University of California, San Diego. Dr. Bredesen also directed the Program on Aging at the Burnham Institute before joining the Buck Institute in 1998 as the founding President and CEO.

Dr. Bredesen’s research explores previously uncharted territory in explaining the physical mechanism behind the erosion of memory seen in Alzheimer’s disease, and has opened the door to new approaches to treatment. This work has led to the identification of several new therapeutic processes that are showing remarkable early results. Dr. Bredesen is a prodigious innovator in medicine, with over thirty patents to his name. Notably, he put much of his findings and research into the 2017 New York Times bestseller, The End of Alzheimer’s.

Dr. Bredesen has written several books, including two New York Times Bestsellers, that have forever changed the way we perceive the scourge of Alzheimer’s disease. His most recent book, The First Survivors of Alzheimer’s, presents the stories of seven individuals who reversed their cognitive decline using the ReCODE Protocol.